US 12,291,569 B2
Antibodies and nucleotide sequences, and uses thereof
Björn Frendéus, Lund (SE); Ingrid Teige, Lund (SE); Monika Semmrich, Malmö (SE); Linda Mårtensson, Bjärred (SE); and Petra Holmkvist, Kävlinge (SE)
Assigned to BIOINVENT INTERNATIONAL AB, Lund (SE)
Appl. No. 17/272,740
Filed by BIOINVENT INTERNATIONAL AB, Lund (SE)
PCT Filed Sep. 3, 2019, PCT No. PCT/EP2019/073488
§ 371(c)(1), (2) Date Mar. 2, 2021,
PCT Pub. No. WO2020/049001, PCT Pub. Date Mar. 12, 2020.
Claims priority of application No. 18192311 (EP), filed on Sep. 3, 2018.
Prior Publication US 2022/0041723 A1, Feb. 10, 2022
Int. Cl. C07K 16/28 (2006.01); A61P 35/00 (2006.01); C12N 7/00 (2006.01); C12N 15/86 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2818 (2013.01) [A61P 35/00 (2018.01); C12N 7/00 (2013.01); C12N 15/86 (2013.01); A61K 2039/505 (2013.01); C07K 2317/33 (2013.01); C07K 2317/565 (2013.01); C07K 2317/732 (2013.01); C07K 2317/76 (2013.01); C12N 2710/24143 (2013.01)] 8 Claims
 
1. An antibody molecule that specifically binds to CTLA-4, wherein the antibody molecule comprises the 6 CDRs having VH-CDR1 of SEQ ID NO: 15, the VH-CDR2 of SEQ ID NO: 16, the VH-CDR3 of SEQ ID NO: 17, the VL-CDR1 of SEQ ID NO: 10, the VL-CDR2 of SEQ ID NO: 18, and the VL-CDR3 of SEQ ID NO: 19, or comprises the 6 CDRs having VH-CDR1 of SEQ ID NO: 22, the VH-CDR2 of SEQ ID NO: 23, the VH-CDR3 of SEQ ID NO: 24, the VL-CDR1 of SEQ ID NO: 10, the VL-CDR2 of SEQ ID NO: 25, and the VL-CDR3 of SEQ ID NO: 26.